Streaming Web-based Exercise At Home: A Pilot Study

Sponsor
Celina Shirazipour (Other)
Overall Status
Recruiting
CT.gov ID
NCT04282967
Collaborator
(none)
20
1
1
37.8
0.5

Study Details

Study Description

Brief Summary

This is a single-arm pilot study to evaluate the use of web-based video conferencing as a method of exercise training delivery. This study will include 10 female breast cancer survivors and 10 male prostate cancer survivors. For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Exercise
Early Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
IIT2019-14-SHIRAZIP-SWEAT: Streaming Web-based Exercise At Home: A Pilot Study
Actual Study Start Date :
Jul 7, 2020
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exercise

For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.

Behavioral: Exercise
For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.

Outcome Measures

Primary Outcome Measures

  1. Attendance [12 weeks]

    Explore adherence to intervention delivery measured through attendance (frequency of Skype sessions attended and fully completed)

  2. Adherence [12 weeks]

    Explore adherence to intervention delivery measured through retention (participation from baseline through final assessment)

  3. Patient consent [1 day]

    Explore adherence to intervention delivery measured through percentage of patients approached who sign consent

  4. Manipulation check [12 weeks]

    Explore adherence to intervention delivery measured through scores on manipulation check after each session (2 questions asked by exercise physiologist on sound and visual clarity of the session)

Secondary Outcome Measures

  1. Changes in oxygen uptake (baseline - mid-study visit) [12 weeks]

    Change in vO2 submax measurement (rate of oxygen uptake during exercise) between baseline & mid-study visits as measured by Bruce submaximal treadmill test.

  2. Changes in oxygen uptake (mid-study visit - end of study visit) [12 weeks]

    Change in vO2 submax measurement (rate of oxygen uptake during exercise) between mid-study & end of study visits as measured by Bruce submaximal treadmill test.

  3. Changes in oxygen uptake (baseline - end of study visit) [24 weeks]

    Change in vO2 submax measurement (rate of oxygen uptake during exercise) between baseline & end of study visits as measured by Bruce submaximal treadmill test.

  4. Changes in strength test (baseline - mid-study visit) [12 weeks]

    Change in muscle strength measurement between baseline & mid-study visits as measured by grip strength test and leg press.

  5. Changes in strength test (mid-study visit - end of study visit) [12 weeks]

    Change in muscle strength measurement between mid-study & end of study visits as measured by grip strength test and leg press.

  6. Changes in strength test (baseline - end of study visit) [24 weeks]

    Change in muscle strength measurement between baseline & end of study visits as measured by grip strength test and leg press.

  7. Changes in resting heart rate (baseline - mid-study visit) [12 weeks]

    Changes in resting heart rate between Baseline & mid-study visits

  8. Changes in resting heart rate (mid-study visit - end of study visit) [12 weeks]

    Changes in resting heart rate between mid-study & end of study visits

  9. Changes in resting heart rate (baseline - end of study visit) [24 weeks]

    Changes in resting heart rate between Baseline & end of study visits

  10. Changes in body composition (baseline - mid-study visit) [12 weeks]

    Changes in body composition between baseline & mid-study visits as measured by InBody (non-invasive body composition analysis that calculates weight, skeletal muscle mass, fat mass, BMI, and body fat percent using Bio-Electrical Impedance Analysis).

  11. Changes in body composition (mid-study visit - end of study visit) [12 weeks]

    Changes in body composition between mid-study & end of study visits as measured by InBody (non-invasive body composition analysis that calculates weight, skeletal muscle mass, fat mass, BMI, and body fat percent using Bio-Electrical Impedance Analysis).

  12. Changes in body composition (baseline - end of study visit) [24 weeks]

    Change in body composition between baseline & end of study visits as measured by InBody (non-invasive body composition analysis that calculates weight, skeletal muscle mass, fat mass, BMI, and body fat percent using Bio-Electrical Impedance Analysis).

  13. Subjective impact [24 weeks]

    Subjective impact of exercise intervention as measured by changes in participant-reported rating of exercise self-efficacy and intentions to remain active

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male previously diagnosed with prostate cancer or female previously diagnosed with breast cancer.

  • For breast cancer, minimum of 3 months post-active treatment completion. Active treatment includes chemotherapy, biologic therapy, radiation therapy, surgery, and any combination. Long-term hormonal/biologic treatments are acceptable.

  • For prostate cancer, minimum of 3 months post-active treatment completion. Active treatment includes chemotherapy, biologic therapy, radiation therapy, surgery, and any combination. Long-term hormonal/biologic treatments are acceptable, except for androgen receptor-targeted therapies (such as enzalutamide, apalutamide, darolutamide, or abiraterone). Patients currently on active surveillance are eligible even if they have not received prior anti-cancer treatment.

  • Has access to tablet, laptop, or desktop computer with video capabilities connected to the internet with a screen at least 13 inches across.

  • Physically able to complete modified Bruce submaximal treadmill test, leg strength test, grip strength test, and InBody per patient self-assessment.

  • Physician clearance to participate in this study. Can be done through review of patients' medical records.

  • Ability to read, write, and understand English.

  • Has a chair at home to use for exercise that is not on wheels and has a solid back (not a reclining chair).

  • Ambulatory without assistance.

  • Has a clear 5 x 6-foot space at home in which to exercise.

  • Age >18 years.

  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

Exclusion Criteria:
  • Active treatment planned within the next 6 months. Active treatment includes chemotherapy, biologic therapy, radiation therapy, surgery, and any combination. Long-term hormonal/biologic treatments are acceptable, except for AR-targeted therapies for prostate cancer.

  • Known metastatic disease.

  • Grade 3 or higher peripheral neuropathy.

  • Major surgery within 3 months of baseline visit.

  • Positive pregnancy test for women of child-bearing potential.

  • Answers yes to any question on the Physical Activity Readiness Questionnaire unless study participation is cleared by a physician.

  • Known allergy to Fitbit device.

  • Currently meeting physical activity guidelines (score of >23 on Godin-Shephard Leisure-Time Physical Activity Questionnaire).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cedars Sinai Medical Center Los Angeles California United States 90048

Sponsors and Collaborators

  • Celina Shirazipour

Investigators

  • Principal Investigator: Celina Shirazipour, PhD, Cedars-Sinai Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Celina Shirazipour, Assistant Professor, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT04282967
Other Study ID Numbers:
  • IIT2019-14-SHIRAZIP-SWEAT
First Posted:
Feb 25, 2020
Last Update Posted:
Mar 14, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Celina Shirazipour, Assistant Professor, Cedars-Sinai Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 14, 2022